Validation of a differential in Situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 5-6, 2010, Pages 278-285

  Brouwers, Joachim ^a   Mols, Raf ^a   Annaert, Pieter ^a   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Biopharmaceutics; Drug interactions; In situ perfusion; Intestinal absorption; Permeability

Indexed keywords

AMPRENAVIR; ATENOLOL; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; EXCIPIENT; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; KETOCONAZOLE; PROPRANOLOL; TALINOLOL; TOCOFERSOLAN; VERAPAMIL; ALPHA TOCOPHEROL; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMIC ACID DERIVATIVE; MACROGOL DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; SULFONAMIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CANNULA; CELL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG INHIBITION; DRUG PENETRATION; DRUG TRANSPORT; INTESTINE ABSORPTION; MALE; MESENTERIC ARTERY; MESENTERY BLOOD FLOW; MOLECULAR PROBE; NONHUMAN; PERFUSION; PERIPHERAL CIRCULATION; PUMP; RAT; VALIDATION STUDY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; DRUG INTERACTION; PROCEDURES; SPLANCHNIC BLOOD FLOW; WISTAR RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBAMATES; DRUG INTERACTIONS; INTESTINAL ABSORPTION; KETOCONAZOLE; MALE; P-GLYCOPROTEIN; PERFUSION; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SPLANCHNIC CIRCULATION; SULFONAMIDES; VERAPAMIL; VITAMIN E;

EID: 77955701355     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.710     Document Type: Article

References (22)

1. Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002; 41: 235-253.
2. Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 2004; 5: 109-124.
3. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009; 61: 541-558. DOI: 10.1211/jpp/61.05.0002.
4. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical Implications. Clin Pharmacokinet 1999; 36: 233-254.
5. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009; 26: 2039-2054. DOI: 10.1007/s11095-009-9924-0.
6. Deferme S, Annaert P, Augustijns P. In vitro screening models to assess intestinal drug absorption and metabolism. In Drug Absorption Studies, Ehrhardt C, Kim K (eds). Springer: New York, 2008; 182-215.
7. Cummins CL, Salphati L, Reid MJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 2003; 305: 306-314. DOI: 10.1124/jpet.102.044719. (Pubitemid 36373865)
8. Mols R, Brouwers J, Schinkel AH, Annaert P, Augustijns P. Intestinal perfusion with mesenteric blood sampling in wild-type and knockout mice: evaluation of a novel tool in biopharmaceutical drug profiling. Drug Metab Dispos 2009; 37: 1334-1337. DOI: 10.1124/dmd.109.026591.
9. Mols R, Deferme S, Augustijns P. Sulfasalazine transport in in-vitro, ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts. J Pharm Pharmacol 2005; 57: 1565-1573. DOI: 10.1211/jpp.57.12.0006. (Pubitemid 41752270)
10. Cao J, Chen X, Liang J, et al. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Drug Metab Dispos 2007; 35: 539-553. DOI: 10.1124/dmd.106.010801. (Pubitemid 46513256)
11. Xia CQ, Milton MN, Gan L. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 2007; 8: 341-363.
12. Usansky HH, Hu P, Sinko PJ. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. Drug Metab Dispos 2008; 36: 863-869. DOI: 10.1124/dmd.107.017483. (Pubitemid 351574883)
13. Hanafy A, Langguth P, Spahn-Langguth H. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur J Pharm Sci 2001; 12: 405-415. DOI: 10.1016/S0928-0987(00)00195-0. (Pubitemid 32166739)
14. Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P. Intestinal drug efflux: formulation and food effects. Adv Drug Deliv Rev 2001; 50: S13-S31. DOI: 10.1016/S0169-409X(01)00183-1. (Pubitemid 32905353)
15. Varma MVS, Panchagnula R. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J Pharm Sci 2005; 94: 1694-1704. DOI: 10.1002/jps.20309. (Pubitemid 41360864)
16. Augustijns P, Mols R. HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. J Pharm Biomed Anal 2004; 34: 971-978. DOI: 10.1016/j.jpba.2003.11.016. (Pubitemid 38296400)
17. Brouwers J, Tack J, Augustijns P. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. Pharm Res 2007; 24: 1862-1869. DOI: 10.1007/s11095-007-9307-3. (Pubitemid 47389240)
18. Hayeshi R, Hilgendorf C, Artursson P, et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 2008; 35: 383-396. DOI: 10.1016/j.ejps. 2008.08.004.
19. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 1999; 39: 211-238. DOI: 10.1016/S0169- 409X(99)00027-7. (Pubitemid 29430237)
20. Yu L, Bridgers A, Polli J, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 1999; 16: 1812-1817. DOI: 10.1023/A:1018939006780.
21. Brouwers J, Tack J, Lammert F, Augustijns P. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. J Pharm Sci 2006; 95: 372-383. DOI: 10.1002/jps.20553. (Pubitemid 43241979)
22. Collnot E, Baldes C, Wempe MF, et al. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release 2006; 111: 35-40. DOI: 10.1016/j.jconrel.2005.11. 005. (Pubitemid 43289992)